A comprehensive understanding of the molecular structure, ligand interactions and regulation of T-cadherin expression is necessary to fully understand its multifaceted roles in various diseases. This information lays the groundwork for investigating the specific contribution of T-cadherin to cardiovascular diseases, metabolic disorders and cancer.

The 3′ untranslated region of the T-cadherin-encoding gene CDH13 has a microRNA (miR)-377-3p binding site that controls T-cadherin protein expression (14). T-cadherin is a member of the ‘atypical cadherin’ subgroup of the cadherin superfamily. The five Ca²⁺-binding domains present in T-cadherin are important for homo- and hetero-dimerization and interactions with other T-cadherin molecules in the vascular and neurological systems (12) (Fig. 1). Similar to other traditional cadherins, such as epithelial-cadherin (E-cadherin) and neural-cadherin (N-cadherin), T-cadherin is linked to the cell membrane by a GPI anchor; however, T-cadherin does not have intracellular and transmembrane structural domains (15). Protein distribution of T-cadherin within plasma membrane rafts is often guided by the presence of the GPI anchor (11), a structural component that provides dynamic modulation of cell adhesion and may play a role in signal transduction via lipid raft microregions. The dual ligand-binding capability of T-cadherin implies that its extracellular domain may contain multiple binding sites, as its extracellular region acts as a receptor for both LDL and HMW adiponectin (16). In vitro experiments have shown that adiponectin binds to cells expressing T-cadherin but not adiponectin receptor (AdipoR)1 or calreticulin. AdipoR and calreticulin may require additional co-receptors or accessory proteins to acquire the ability to bind natural HMW adiponectin. T-cadherin knockout notably reduces adiponectin binding to cells of the 293 cell line, Chinese hamster ovary cells and C2C12 myotubes. These findings indicate that T-cadherin is the primary binding partner of native adiponectin (17,18) Importantly, T-cadherin is a receptor for hexameric and HMW adiponectin, but not for trimeric or globular adiponectin (19). A study by Fukuda et al (20) showed that the binding of adiponectin to T-cadherin required the extracellular EC1-EC2 region of T-cadherin, and that the pro-domain of T-cadherin played a role in binding with adiponectin. The extracellular cadherin repeat (EC1-EC2) region overlaps with the reported homologous transmembrane region of T-cadherin (21). Notably, compared with the mature form comprising 100 kDa T-cadherin without the pro-domain, the 130 kDa T-cadherin form with the pro-domain shows a greater binding affinity for adiponectin. The 130 kDa form is also more likely to be expressed on the surface of endothelial cells both in vitro and in vivo than the mature form, demonstrating positive feedback regulation of T-cadherin by adiponectin (20). Adiponectin binding further increases membrane expression and functional activity of 130 kDa T-cadherin, continuously elevating T-cadherin abundance at the post-translational level. A study by Bochkov et al (22) primarily showed that the atypical lipoprotein-binding protein P105 that is present on the vascular smooth muscle membrane of humans and rats was T-cadherin, providing evidence that the mechanism underlying binding of LDL to T-cadherin may be similar to that mediating homophilic cadherin-cadherin interactions. A subsequent study revealed that T-cadherin is expressed in Escherichia coli with a GPI anchor signal sequence but without GPI modification, and that recombinant human T-cadherin expressed in 293 cells without a GPI anchor signal sequence cannot bind to lipoproteins, providing evidence that the GPI anchor of T-cadherin is important for lipoprotein binding (23). Previous studies have provided evidence that T-cadherin is a physiological receptor for LDL (24–26). T-cadherin binds to LDL on the cell surface, triggering intracellular calcium ion mobilization, increasing tyrosine phosphorylation and stimulating ERK1/2 and NF-κB to promote cell proliferation, thereby converting extracellular LDL into mitogenic signals (25,27).

T-cadherin accumulation in cardiovascular tissues, such as the aorta, heart and skeletal muscles, allows adiponectin to exert cardioprotective effects (28). Clinical research has shown a notable association between serum HMW adiponectin levels and T-cadherin expression. The binding between T-cadherin in HMW adiponectin is specific and independent of other known adiponectin receptors, such as AdipoR1 and AdipoR2 (17,29). In addition to its role as a receptor for adiponectin, T-cadherin contributes to the pleiotropic organ-protective effects of adiponectin. T-cadherin-dependent secretion of adiponectin via exosomes in the cardiovascular system improves vascular homeostasis and myocardial regeneration, and is the predominant mechanism underlying therapeutic effects of mesenchymal stem cells (MSCs) (30). In muscle and endothelial cells, T-cadherin binds to adiponectin to activate exosome secretion. Additionally, inhibition of the AdipoR1/R2 signaling pathway, potentially mediated by competitive binding of adiponectin to T-cadherin, activates the ERK1/2/MAPK pathway, promoting tissue repair and cell proliferation (Fig. 1) (30,31).

Vascular endothelial cells, vascular smooth muscle cells and pericytes are the primary cells of the cardiovascular system that express T-cadherin (32,33). Immunofluorescence results in a previous study showed that T-cadherin is markedly expressed in the basal layer of healthy arteries and is closely linked to the functional control of pericytes (33). Furthermore, its presence in cardiac tissues, particularly in the coronary endothelium and cardiomyocytes, raises the possibility that T-cadherin plays a cardioprotective role (20,34).

As a receptor for LDL and HMW adiponectin, T-cadherin possesses dual ligand-binding capabilities (12,16,25). These two ligands exert opposing effects on the cardiovascular system. When LDL binds to T-cadherin, it triggers the calcium signaling cascade, accelerating the formation of atherosclerotic plaques by promoting endothelial cell migration, proliferation and inflammatory responses (25,35). HMW adiponectin accumulation in cardiovascular tissues via T-cadherin improves insulin resistance and inhibits vascular inflammation by increasing exosome production and release while decreasing cellular ceramide accumulation (20,34,36) (Fig. 1). This process activates Notch signaling (37), a pathway closely associated with adiponectin-dependent vascular regeneration and myocardial protection (38,39). Although T-cadherin is generally associated with the cardiovascular protective effects of adiponectin, it also displays an association with non-alcoholic fatty liver disease (NAFLD) due to shared metabolic dysfunction. Reduced adiponectin signals via its receptors, including T-cadherin, cause insulin resistance and hepatic fat accumulation in NAFLD (40). Additionally, a study has shown that genetic variations, known as polymorphisms, in CDH13 are associated with NAFLD-related metabolic diseases, such as type 2 diabetes (T2D) and metabolic syndrome (40). A previous study has shown that a high fatty liver index score can predict the risk of T2D. It is plausible that CDH13 alleles are associated with T2D through liver indicators (41).

Atherosclerosis, assessed using carotid intima-media thickness (IMT), is closely associated with NAFLD (42). The dual role of T-cadherin as a receptor for both cardioprotective adiponectin and atherogenic LDL suggests that it is an important metabolic sensor that may influence NAFLD and its associated cardiovascular risk. T-cadherin is uniquely expressed on the plasma membranes of vascular endothelial cells, smooth muscle cells and cardiomyocytes. Its distribution is not uniform but rather concentrated at signaling hubs such as membrane microdomains rich in caveolin proteins. This ‘strategic localization’ enables efficient binding to ligands in the bloodstream (such as adiponectin) and initiates signaling pathways that regulate cell growth, survival and function. Due to the strategic placement and dual ligand-binding capabilities of T-cadherin within the cardiovascular system, its dysregulation or altered expression is expected to contribute towards the development of major cardiovascular disorders (19,43,44). The following sections discuss the evidence linking T-cadherin to atherosclerosis, hypertension, heart failure and diabetes.

T-cadherin regulates lipid metabolism, which directly affects the development of atherosclerotic plaques (45). A study by Göddeke et al (45), while studying the role of T-cadherin in 3T3-L1 adipocyte differentiation, observed that T-cadherin expression was highest in undifferentiated adipocytes and almost undetectable in mature adipocytes. During adipogenesis, T-cadherin knockdown has been shown to reduce the expression of adipogenic genes, including peroxisome proliferator activated receptor γ and CCAAT enhancer binding protein α. Additionally, the authors of the study noted that T-cadherin knockdown resulted in a reduction in both fatty acid uptake and lipid content in developing adipocytes (45). Another study by Sysoeva et al (16) subsequently reported that LDL stimulated adipogenic differentiation, whereas T-cadherin expression appears to mitigate the promotional effect of LDL on lipid droplet accumulation. When LDL was added to adipogenic and standard media, the proportion of lipid droplet-positive cells in both T-cadherin^−/− MSCs and wild-type MSCs markedly increased, suggesting that LDL promotes lipid droplet accumulation. However, the proportion of lipid droplet-positive cells in wild-type MSCs was lower compared with that in T-cadherin^−/− MSCs, indicating that T-cadherin plays a specific role in mitigating the impact of LDL on adipogenic differentiation (16).

Atherosclerosis is characterized by excessive accumulation of lipids in the intima of the cardiovascular system (46). By inhibiting the expression of miR-101-3p, erythroferrone can increase phospholipid-transporting ATPase ABCA1 expression and cholesterol efflux, thereby increasing T-cadherin expression and high-density lipoprotein cholesterol levels in the circulation, as well as the efficiency of reverse cholesterol transport, thereby inhibiting the development of atherosclerosis (Fig. 1) (39). Furthermore, a study on T-cadherin/apolipoprotein E dual-knockout model mice demonstrated markedly elevated plasma lipocalin levels in T-cadherin-deficient mice reared on a high-cholesterol diet compared with T-cadherin-expressing mice, alongside a notable increase in atherosclerotic plaque area and neointimal thickness, indicating that T-cadherin is an important receptor for the protective function of adiponectin (47).

Atherosclerosis is often accompanied by neovascularization, a process induced by inflammation and tissue ischemia. Neovascularization within the plaque extends to the intima at the site of vascular injury, which may lead to intra-plaque hemorrhage and rupture, thereby promoting the progression and acute onset of atherosclerosis (48–50). Notably, T-cadherin promotes angiogenesis by facilitating vascular cell cycle progression and inducing cell de-adhesion, thereby promoting the migration of smooth muscle and endothelial cells (33,48,51). In human umbilical vein endothelial cells, T-cadherin overexpression leads to impaired endothelial barrier function through chloride-dependent endocytosis and lysosomal degradation of vascular endothelial-cadherin (VE-cadherin), activation of Rho GTPase and increased actin stress fiber assembly (52). It has been further demonstrated that increased T-cadherin expression negatively affects endothelial barrier functions. A study on the human endothelial cell line Ea.hy926 showed that overexpression of T-cadherin is linked to lower VE-cadherin and β-catenin mRNA levels, resulting in the loss of endothelial barrier function (53). The present review speculates that under pathological conditions, overexpression of T-cadherin further suppresses endothelial function and increases endothelial permeability. Additionally, a previous study has shown that the extracellular cadherin repeats EC1 and EC5 of T-cadherin are necessary for its ability to stimulate endothelial cell angiogenic behavior (51). These findings suggest that T-cadherin promotes the progression of atherosclerosis.

The severity of atherosclerotic lesions is closely associated with immune cell infiltration (54). It is hypothesized that T-cadherin may influence plaque progression by modulating CD8⁺ T cell functions. In advanced plaques, depletion of CD8⁺ T cells reduces smooth muscle apoptosis and improves plaque stability (54). Furthermore, animal experiments have demonstrated that T-cadherin deficiency causes endothelial cell death by inhibiting the PI3K/Akt pathway, which leads to decreased Akt phosphorylation, rather than by inhibiting endothelial nitric oxide synthase, which leads to decreased production of endothelial cell nitrogen oxides and a marked reduction in vasodilatory function. These changes in endothelial cells (55) (Fig. 1) exacerbate oxidative stress and the release of inflammatory factors, such as IL-1β and IL-6, which further encourage macrophage infiltration into the plaque (53). Adiponectin reduces the intra-plaque inflammatory response by blocking inflammatory signaling pathways, such as the NF-κB signaling pathway, via mechanisms dependent on T-cadherin (56). A clinical study has shown that patients with particular genotypes, for example the thymine allele, carrying the CDH13 rs12444338 single-nucleotide polymorphism (SNP), have lower plasma T-cadherin levels, although the carotid IMT of these patients was lower than patients without these SNPs. These findings suggest that this particular genotype may have a protective effect against atherosclerosis (56). Furthermore, T-cadherin plays dual roles in diabetes-related vasculopathy; increases in T-cadherin expression increase insulin secretion, while the excessive upregulation of T-cadherin may worsen endothelial insulin resistance (35,37).

Several studies have proposed treatment options for atherosclerosis based on the regulatory mechanisms of T-cadherin. Supplementation with recombinant adiponectin or increased T-cadherin expression can prevent lipid accumulation and inflammatory responses in plaques, protecting the heart from stress-induced pathological remodeling (39,47,57). Generating specific antibodies or small molecule inhibitors to prevent LDL from binding to T-cadherin can reduce its pro-atherosclerotic effects (25,56). Furthermore, CRISPR/Cas9 technology can be used to alter CDH13 polymorphisms (58), while miRs, such as miR-101-3p, can be used to modify T-cadherin expression for improving the efficacy of reverse cholesterol transporters (16,39).

In total, ~30% of adults have hypertension, one of the most prevalent cardiovascular conditions worldwide. Hypertension is closely associated with metabolic irregularities and the risk of cardiovascular events (59). SNPs in CDH13 have been linked to hypertension in genome-wide association studies (GWASs). Reduced circulating T-cadherin levels and carotid IMT are linked to the CDH13 SNP rs12444338, indicating that this genotype may exert antihypertensive effects by altering the vascular structure (56). CDH13-specific SNPs, such as rs12444338 and rs1048612, have been linked to variation in systolic blood pressure levels in hypertensive patients, accounting for ~1% of the phenotypic variance in blood pressure (60). Notably, these associations vary by population: In the South Korean population, carriers of the rs6565105 allele display elevated levels of LDL cholesterol compared with other genotypes (61), which may indirectly increase the risk of elevated blood pressure, whereas in African Americans, the effect of CDH13 SNPs on systolic blood pressure has been identified in independent samples (60). These findings imply that CDH13 polymorphism may regulate blood pressure differently in different ethnicities, and metabolic pathways may modulate its effects. A previous study showed that the CDH13 rs11646213 polymorphism is associated with a lower risk of hypertension compared with other SNPs (62). These results suggest that certain CDH13 polymorphisms may protect against hypertension. Notably, the greatest signal associated with blood pressure features, such as systolic and diastolic blood pressure, as well as hypertension, was the rs7500599 intron SNP of CDH13, which also interacts with particulate matter exposure (63). These findings suggest that variations in CDH13 may affect the susceptibility of an individual to environmental stimuli, thereby affecting the likelihood of developing hypertension.

Animal models offer new perspectives on the pathophysiology of hypertension. Based on comparative studies of T-cadherin-knockout and wild-type mice, it has been reported that T-cadherin plays an important role in controlling blood pressure and endurance. Furthermore, T-cadherin knockout mice demonstrate a marked increase in systolic blood pressure and reduced endurance following exercise compared with wild-type mice, indicating that T-cadherin plays a notable role in regulating vascular reactivity and that T-cadherin deficiency reduces the compensatory capacity for cardiovascular functions (32). Furthermore, in a model of angiotensin II-mediated endothelial dysfunction, T-cadherin-deficient mice show markedly lower reactive oxygen species generation and NADPH oxidase 2 (Nox2) expression than their wild-type counterparts (53). These findings suggest that T-cadherin plays a role in controlling angiotensin II-induced vascular reactivity, which in turn influences blood pressure regulation.

Compared with rats with normal blood pressure, the levels of ceramide in the arterial tissue of spontaneously hypertensive rats have been demonstrated to be markedly elevated (64). A further study showed that ceramide is associated with thromboxane A2, a protein that may cause endothelial dysfunction in hypertension (64). Similar associations between ceramide levels and blood pressure have been reported in patients with hypertension. In patients with primary hypertension, plasma ceramide levels increase stepwise with the severity of hypertension. Ceramide levels in patients with stage 1 hypertension are between those in individuals with healthy blood pressure and stage 2–3 hypertension (65). A previous study has shown that ceramide/sphingosine-1-phosphate regulators play a role in blood pressure regulation in patients with hypertension (66). The adiponectin/T-cadherin system reduces intracellular ceramide levels via exosome secretion (34).

The interaction between T-cadherin and VE-cadherin was further supported by the observation that overexpression of T-cadherin in cultured human endothelial cells decreases VE-cadherin mRNA expression. This interaction may disrupt endothelial barrier function and affect vascular tone, which may have a stabilizing effect on vascularity and blood pressure regulation (53). According to previous studies, T-cadherin regulates blood pressure via several mechanisms, including oxidative stress, vascular remodeling and endothelial function modification (32,53,57). Although T-cadherin has been linked to hypertension in several studies, the generalizability of these results may be affected by confounding variables and population variations. A study conducted in Amish and European populations have validated statistically significant effects of CDH13 SNPs on blood pressure (odds ratio, 1.2–2.0); however, phenotypic evaluations may be complicated due to the use of antihypertensive drugs (60). The study further showed that after controlling for confounders, the effect of certain CDH13 SNPs on hypertension among African Americans was weakly significant (P=0.04) (60), indicating that contextual or epigenetic variables may alter the impact of genotype on hypertensive susceptibility. Cross-ethnic large-sample cohort studies and the integration of multi-omics data are needed to elucidate the precise role of CDH13 polymorphisms in hypertension and thoroughly examine its molecular network to identify novel targets for the precise treatment of hypertension.

Heart failure, a common outcome in several cardiovascular disorders, is becoming a notable public health issue. Patients with heart failure typically have a low quality of life in addition to high hospitalization and mortality rates (67–69). According to estimates, 1–2% of all individuals in industrialized cultures have heart failure, while in those >70 years of age, the prevalence of heart failure is >10%. In Europe, the lifetime risk of the disease is ~33% for males and 28% for females aged >55 years (70), whereas in the US, the lifetime risk is 20% for those aged >40 years (71). Compared with Western populations, heart failure is more severe and develops at a younger age in Asians and in low- and middle-income nations (69,72). When MSCs are used to treat pressure-overload heart failure, the adiponectin/T-cadherin system plays a key role in promoting myocardial regeneration and reducing oxidative stress by increasing exosome production and secretion. Experiments have demonstrated that mice lacking T-cadherin or adiponectin have much lower exosome counts and do not benefit from MSC therapy (30,73,74).

Heart failure frequently coexists with cardiac remodeling, which is defined as changes in the structure and function of the heart, and includes perivascular and interstitial fibrosis, ventricular arrhythmias (75) and structural remodeling. These changes alter the composition and structure of the heart, which in turn causes ventricular hypertrophy, cardiac fibrosis and heart failure (76,77). T-cadherin plays a key role in heart failure by regulating oxidative stress and inflammatory signaling implicated in cardiac fibrosis. The production of reactive oxygen species and Nox2 mRNA expression are markedly downregulated in T-cadherin-deficient mouse models of angiotensin II-induced endothelial dysfunction, indicating that T-cadherin may affect cardiac remodeling by regulating redox homeostasis. Furthermore, the absence of T-cadherin reduces bleomycin-induced lung fibrosis; however, further research is required to determine the precise mechanism by which T-cadherin affects myocardial fibrosis (53). Adiponectin may suppress fibrosis via the CDH13/p38 MAPKγ signaling axis, and reduced CDH13 expression is linked to increased fibroblast activation in pulmonary fibrosis (78). Since cardiac fibrosis is a fundamental pathophysiological alteration in heart failure, CDH13 may be a novel target for myocardial remodeling interventions.

Other calcineurin proteins, including N-cadherin and VE-cadherin, interact functionally with T-cadherin. Abnormal cardiomyocyte coupling in patients with end-stage heart failure may result from deregulation of the obscurin-kinase 1/N-cadherin axis (79). Further research is needed to determine whether a relationship exists between T-cadherin expression and the obscurin-kinase 1/N-cadherin axis in heart failure models. A previous study reported by Fukuda et al (73) identified three novel soluble isoforms of T-cadherin and reported that the 30 kDa isoform was associated with clinically important indicators of heart failure, such as B-type natriuretic peptide. Further studies are needed to determine whether other signaling pathways or molecular mechanisms are involved in heart failure pathology. T-cadherin overexpression can damage endothelial intercellular junction integrity and decrease VE-cadherin mRNA levels, affecting heart function and vascular permeability (53). An ovarian cancer study revealed a regulatory relationship between CDH13 and DNA methyltransferase 1 (DNMT1) (80). Since DNMT1 is important in myocardial hypertrophy and fibrosis, CDH13 may indirectly affect the development of heart failure through epigenetic networks. Future studies using data from various sources, including studies at the cellular level, animal models and clinical investigations, are needed to corroborate the association between T-cadherin and heart failure.

Although the underlying molecular mechanisms are unknown, several studies have linked the plasma levels of adiponectin and T-cadherin to an increased risk of diabetes (37,81,82). In obese individuals and patients with type 2 diabetes, plasma adiponectin levels are often reduced, a finding linked to insulin resistance and β-cell dysfunction (81). This suggests that low adiponectin levels are closely associated with diabetes. An animal study demonstrated that T-cadherin deficiency increases the risk of diabetes (37). Elevated levels of T-cadherin do not directly increase the risk of diabetes; rather, increased soluble T-cadherin levels serve primarily as a biochemical marker of insulin deficiency or impaired insulin signaling (82). Vascular endothelial cells, cardiac muscles, MSCs and skeletal muscles are the predominant cells that express T-cadherin, although pancreatic β-cells also rarely express T-cadherin (37,57,74,82). Although not expressed in β-cells, the endogenous humoral factor soluble T-cadherin notably promotes β-cell proliferation. Additionally, the Notch and IL-6/STAT3 pathways in pancreatic islets are regulated by T-cadherin (37). The Notch pathway contributes to the differentiation and proliferation of β-cells (83,84), which are promoted by soluble T-cadherin regulation. However, the absence of soluble T-cadherin suppresses the IL-6/STAT3 pathway and the activity of protein kinases involved in β-cell proliferation and apoptosis (37,85–87). Notably, the proliferative effects of T-cadherin are tissue specific; knocking out T-cadherin in the heart or skeletal muscles does not impact β-cell function (82). However, in mice with streptozotocin-induced diabetes, endothelial cell-specific T-cadherin knockout is associated with a 26% decrease in plasma soluble T-cadherin levels, which is accompanied by a marked increase in blood glucose (82). These findings imply that T-cadherin produced by endothelial cells may modulate β-cell activity or systemic insulin sensitivity, thereby regulating glucose metabolism.

A previous study demonstrated that diabetic mouse models, such as leptin receptor-deficient db/db model mice, have increased levels of plasma soluble T-cadherin (82), which could be an adaptive reaction to the compensatory requirement for β-cell activity. Furthermore, insulin can positively regulate the production of soluble T-cadherin from endothelial cells through the insulin receptor/Akt signaling pathway, and inadequate insulin secretion or insulin resistance may interfere with this regulatory mechanism (35,37). T-cadherin regulates insulin sensitivity via two different mechanisms: i) The effects of adiponectin on ceramide turnover are mediated via the T-cadherin/adiponectin signaling pathway, which improves endothelial function and suppresses inflammatory responses, resulting in increased insulin sensitivity (Fig. 1) (12,16,81); and ii) T-cadherin upregulation in vascular cells may interfere with insulin receptor signaling, resulting in endothelial insulin resistance (12,88).

GWASs have shown that the risk of diabetes is closely associated with CDH13 polymorphism. The minor allele at the rs3865188 locus may have a protective effect against diabetes (OR, 0.71; 95% CI, 0.58–0.88; P=0.002), whereas the T-allele at the rs11646213 locus is associated with an elevated risk of T2D (OR, 1.11; 95% CI, 1.04–1.18; P=0.001) (41,89). Notably, the rs11646213 locus is also associated with elevated body mass index (P=0.03), indicating that CDH13 polymorphisms may influence metabolic pathways associated with obesity, thereby indirectly increasing the risk of T2D (41). Although CDH13 polymorphisms are markedly associated with T2D in white populations (42), in Han Chinese populations the rs4783244 locus is not significantly associated with T2D (P=0.56), whereas the guanine-allele of rs4311394 may be associated with an increased risk of T2D (OR, 1.20; 95% CI, 1.01–1.41) (90). These differences may stem from the modifying effects of the genetic background or environmental factors. Similarly, the rs11646213 and rs3865188 variants are associated with the prevalence, incidence and progression of type 1 diabetic nephropathy and this association may depend on plasma adiponectin levels (89). The absence of T-cadherin in the vascular segments of T2D models leads to endothelial dysfunction, providing evidence that T-cadherin is involved in the pathogenesis of T2D complications (55).

There has been limited research directly linking T-cadherin to diabetes (12); additional research is needed to determine its precise role in the vascular endothelium, β-cells and insulin signaling. Future research should also concentrate on the molecular mechanism of T-cadherin/adiponectin interactions, variations in CDH13 polymorphisms and the possibility of targeting this receptor for the treatment of diabetes. Furthermore, a bidirectional research strategy of validating mechanistic targets derived from model systems in well-phenotyped clinical cohorts, and conversely, using genetic or phenotypic associations discovered in cohorts to inform new mechanistic studies, will be essential to de-risk and accelerate the development of T-cadherin-targeted therapies.

Although T-cadherin has a notable impact on cardiovascular and metabolic health, it also plays a prominent role in cancer biology. Unlike conventional cadherins, which are typically associated with cancer progression, T-cadherin frequently functions as a tumor suppressor. The loss of T-cadherin expression, primarily due to CDH13 promoter hypermethylation, represents a prevalent characteristic in several epithelial malignancies (91–94).